Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| PVLA | CLUSTER | neutral | 2/10 | Two Palvella insiders, COO Kathleen Goin and Director George Jenkins, sold a combined $310K in open-market shares over a | Oct 23, 2026 |
| APVO | 8-K | neutral | 2/10 | Aptevo Therapeutics filed an 8-K to amend its shareholder rights plan (poison pill), extending the expiration date by on | Oct 23, 2026 |
| ENSC | S-3 | bearish | 7/10 | Ensysce Biosciences filed an S-3 registration statement to register up to 433,907,000 shares of common stock for resale | Oct 23, 2026 |
| PHAT | 8-K | bearish | 6/10 | Phathom disclosed that BDR Pharmaceuticals has sued the FDA challenging the agency's refusal to accept an ANDA referenci | Oct 23, 2026 |
| MTEX | 8-K/A | bearish | 5/10 | Mannatech filed this 8-K/A to add the required auditor letter (Exhibit 16.1) from former auditor BDO USA, P.C., confirmi | Oct 23, 2026 |
| IRD | 144 | neutral | 2/10 | Benjamin R. Yerxa, an officer of Opus Genetics, filed a Form 144 notice of intent to sell 33,189 shares of common stock, | Oct 23, 2026 |
| ACAD | 8-K | neutral | 3/10 | Acadia Pharmaceuticals filed an 8-K confirming the departure of Elizabeth H.Z. Thompson, Ph.D., Executive Vice President | Oct 23, 2026 |
| TNYA | DEF 14A | bearish | 6/10 | Tenaya Therapeutics is soliciting stockholder approval for a reverse stock split (ratio between 1-for-10 and 1-for-25) t | Oct 23, 2026 |
| SAFX | 8-K | bullish | 6/10 | XCF Global (SAFX) entered into a definitive agreement to acquire a sustainable aviation fuel (SAF) production facility i | Oct 23, 2026 |
| AEON | 8-K | neutral | 4/10 | AEON Biopharma filed an 8-K furnishing an October 2026 corporate presentation that outlines its strategy to develop ABP- | Oct 23, 2026 |
| RCUS | 8-K | bearish | 5/10 | Arcus Biosciences closed a public offering of 16,428,572 shares of common stock at $17.50 per share, including full exer | Oct 23, 2026 |
| LYCA | 424B4 | neutral | 5/10 | Lycia Therapeutics priced its IPO at $18.00 per share, selling 17,640,000 shares for total gross proceeds of $317.5 mill | Oct 23, 2026 |
| NAII | DEF 14A | bearish | 6/10 | Natural Alternatives International filed its definitive proxy statement for the December 11, 2026 annual meeting. The fi | Oct 23, 2026 |
| CTOR | 8-K | bearish | 5/10 | Citius Oncology received a Nasdaq extension through April 19, 2027, to regain compliance with the $1.00 minimum bid pric | Oct 23, 2026 |
| BGMS | S-3 | bearish | 7/10 | BGMS filed an S-3 shelf registration to register 1,103,338 shares for resale by selling stockholders who acquired them a | Oct 23, 2026 |
| AKBA | 8-K | bearish | 7/10 | Akebia Therapeutics received a Nasdaq deficiency notice on October 21, 2026, because its common stock bid price closed b | Oct 23, 2026 |
| AMRX | 8-K/A | neutral | 5/10 | Amneal Pharmaceuticals filed an 8-K/A providing unaudited pro forma financial statements for its acquisition of Kashiv B | Oct 23, 2026 |
| JSPR | SC TO-I/A | neutral | 4/10 | Jasper Therapeutics is amending its issuer tender offer to repurchase any and all of its 12,345,707 outstanding warrants | Oct 23, 2026 |
| ALEC | SC 13G | bullish | 5/10 | Deep Track Capital, a healthcare-focused hedge fund, disclosed a new 8.61% passive stake in Alector via a Schedule 13G, | Oct 23, 2026 |
| CLYM | PRESS-RELEASE | bullish | 7/10 | Climb Bio reported additional Phase 1 data for CLYM116/MIL116, an anti-APRIL antibody for IgA nephropathy, at ASN Kidney | Oct 23, 2026 |
| AVBP | PRESS-RELEASE | bullish | 7/10 | ArriVent announced that initial safety and efficacy data from the Phase 1 study of its CDH17-targeted ADC ARR-217 (MRG00 | Oct 23, 2026 |
| AARD | 8-K | mixed | 6/10 | Aardvark Therapeutics reported exploratory efficacy data from its terminated Phase 3 HERO trial and open-label extension | Oct 23, 2026 |
| RDY | 6-K | bearish | 6/10 | Dr. Reddy's reported Q2 FY2027 consolidated revenues of ₹86.7 billion, a 1.5% YoY decline, with profit after tax attribu | Oct 23, 2026 |
| RVMD | INST-CLUSTER | bullish | 4/10 | A strong institutional cluster formed in RVMD during 2026-Q3, with 9 buyers accumulating $421.5M in net new positions ve | Oct 23, 2026 |
| VKTX | INST-CLUSTER | bearish | 4/10 | Viking Therapeutics' Q3 2026 institutional 13F cluster shows net selling pressure: 4 asset managers trimmed positions to | Oct 23, 2026 |
| PFE | INST-CLUSTER | mixed | 3/10 | Five asset managers added $50.3M in PFE positions during Q3 2026, while two large holders trimmed $148.3M. The net selli | Oct 23, 2026 |
| MEDP | INST-CLUSTER | bullish | 4/10 | A bullish institutional cluster formed in Medpace during Q3 2026, with 5 asset managers accumulating $44.1M in net new p | Oct 23, 2026 |
| REGN | INST-CLUSTER | bearish | 4/10 | A mixed institutional cluster in REGN for Q3 2026 shows small buyers accumulating $9.0M while three large sellers exited | Oct 23, 2026 |
| IQV | INST-CLUSTER | neutral | 3/10 | A mixed institutional cluster in IQV shows 5 buyers adding $94.4M in new positions (led by Artemis doubling its stake to | Oct 23, 2026 |
| BMY | INST-CLUSTER | neutral | 3/10 | Four asset managers added BMY positions in Q3 2026, with aggregate buying of $18.3M, while one large holder trimmed $25. | Oct 23, 2026 |